Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
December 2024
in “
Clinical and Experimental Dermatology
”
TLDR Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
The study examines the effects of switching from baricitinib, a JAK1/2 inhibitor, to ritlecitinib, a JAK3/TEC inhibitor, in patients with severe alopecia areata who had inadequate or no response to baricitinib. The findings demonstrate that ritlecitinib significantly improves hair regrowth, quality of life, and psychological well-being in these patients. The study suggests that a lack of response to one JAK inhibitor does not necessarily predict failure with another, indicating potential for ritlecitinib as an effective treatment option for severe alopecia areata.